Why is Marksans Pharma falling/rising?

As of 29-Aug, Marksans Pharma Ltd is experiencing a decline in its stock price, currently at Rs. 168.85, which reflects a decrease of -1.3 (-0.76%). The stock has underperformed significantly, hitting a new 52-week low of Rs. 166.75 today and has been on a consecutive downward trend for the past seven days, resulting in a total decline of -8.46% during this period. Over the last month, the stock has dropped by -25.80%, while its year-to-date performance shows a substantial decline of -43.00%. Despite having a high management efficiency indicated by a return on equity (ROE) of 17.66% and a low debt-to-equity ratio, the company has faced challenges with poor long-term growth, as evidenced by a negative annual operating profit growth rate of -0.29% over the last five years. The recent financial results have also been disappointing, with a significant drop in profit before tax and profit after tax compared to previous quarters.
In the broader market context, Marksans Pharma's performance has been notably worse than the benchmark, with a one-year return of -27.81% compared to the BSE500's decline of -5.40%. This stark contrast highlights the stock's struggle to keep pace with the market, further exacerbated by falling investor participation, as indicated by a -10.66% decrease in delivery volume against the five-day average. The stock's liquidity remains adequate for trading, but the overall sentiment appears negative, as it continues to trade below its moving averages across various time frames. The combination of poor recent performance, disappointing financial results, and a lack of investor confidence contributes to the ongoing decline in Marksans Pharma's stock price.